 |
answer text |
<p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments)
(Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can
be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts"
target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This
set out the approach that the Government proposed to take in assessing the costs and
benefits of the change in the law at a population level, with regard to the rescheduling
of cannabis-based products for medicinal use (CBPM). This framework included potential
savings in treatment costs, giving the example of patients with severe epilepsy for
whom medicinal use of cannabis could reduce the frequency of seizures and reduce the
number of related hospital admissions. This was an initial framework for assessing
this policy and as we develop our knowledge in this area, both on the costs and the
potential benefits, we can revisit and refine these assessments.</p><p>In the meantime,
the National Institute for Health and Care Excellence (NICE) is developing clinical
guidelines on the appropriate use of CBPM based on the best available evidence, and
the National Institute for Health Research is funding further clinical research on
this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf"
target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p>
|
|
